Unite the Power of Immunity for the Fight to Cancer
By developing novel combination immunotherapies utilizing our potent anti-tumor T cell activation technology “T-ignite”, we challenge conquest of intractable cancer, especially “cold tumor”, where conventional therapies are not effective for.
|June 7, 2019||United Immunity, Co. Ltd. increased its capital through third-party allocation of new shares from Mitsubishi UFJ Capital, Co., Ltd. and Axil Capital Partners LLP to accelerate its research and development activity.|
|January 11, 2019||A research article describing the treatment of immune-resistant cold tumors using T-ignite technology was recently published online on the Journal of Clinical Investigation.
Article: Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance. Daisuke Muraoka, … , Naozumi Harada, Hiroshi Shiku, et al. J Clin Invest. 2019. https://doi.org/10.1172/JCI97642.
|July 2, 2018||An investigator-initiated phase 1/2 study on a combination of T-ignite and gene-engineered T cells for the treatment of soft tissue sarcomas has begun in Japan.|
(Next page “Our Science and Technology”)